Journal Mobile Options
Table of Contents
Vol. 2, No. 3-4, 2005
Issue release date: January 2006
Neurodegenerative Dis 2005;2:202–207

Hypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters

Desport J.-C. · Torny F. · Lacoste M. · Preux P.-M. · Couratier P.
aCentre SLA, Service de Neurologie, CHU Dupuytren, bUnité Fonctionnelle de Nutrition, CHU Dupuytren, et cEA 3174, Faculté de Médecine, Limoges, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Despite a reduction in fat-free mass (FFM), a hypermetabolism has been reported with an average of 10% in amyotrophic lateral sclerosis (ALS) patients as compared with a healthy population. The objectives of this study were to confirm the level of hypermetabolism determined by using indirect calorimetry in 168 patients with a probable or a definite ALS and to study correlations with survival. Consecutive evaluations of resting energy expenditure (REE) were performed from diagnosis to the proximity of death in 44 ALS patients. Differences with the calculated value determined a ΔREE. FFM was given by bioimpedance. At T1, REE was significantly increased by an average of 14% as compared with the calculated value. 62.3% of ALS patients were considered as hypermetabolic. REE was correlated in univariate analysis with age, sex, clinical form at onset, presence of a denutrition, weight, FFM, phase angle and ALS Functional Rating Scale (ALSFRS). In multivariate analysis, REE was linked to age and FFM. ΔREE was correlated in univariate analysis with sex, phase angle and manual muscle testing (MMT). In multivariate analysis, age and sex remained significantly correlated. During progression of ALS, REE levels remained higher than calculated values with a trend to decrease at proximity of death, whereas FFM remained stable. From T1, survival was linked to MMT, ALSFRS, vital capacity, REE and phase angle. We confirmed the existence of a stable hypermetabolic state in ALS which depends mainly on age, sex and FFM. REE is a prognostic factor for survival in univariate analysis.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Leigh PN, Ray-Chaudhuri K: Motor neurone disease. J Neurol Neurosurg Psychiatry 1994;57:886–896.
  2. Mitsumoto H, Chad DA, Pioro EP: Course and prognosis; in Mitsumoto H, Chad DA, Pioro EP (eds): Amyotrophic Lateral Sclerosis. Philadelphia, Davis, 1998, pp 151–163.
  3. Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P: Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999;53:1059–1063.
  4. Borasio GD, Voltz R: Palliative care in amyotrophic lateral sclerosis. J Neurol 1997;244(suppl 4):S11–S17.

    External Resources

  5. McDonald ER, Wiedenfeld SA, Hillel A, Carpenter CL, Walter RA: Survival in amyotrophic lateral sclerosis. The role of psychological factors. Arch Neurol 1994;51:17–23.
  6. Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ: Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr 1996;63:130–137.
  7. Desport JC, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P: Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:91–96.
  8. Slowie LA, Paige MS, Antel JP: Nutritional considerations in the management of patients with amyotrophic lateral sclerosis. J Am Diet Assoc 1983;83:44–47.
  9. Desport JC, Preux PM, Truong CT, Vallat JM, Couratier P: Factors correlated with hypermetabolism in amyotrophic lateral sclerosis. Am J Clin Nutr 2001;74:328–334.
  10. Lew EA, Garfinkel L: Variations in mortality by weight among 750,000 men and women. J Chronic Dis 1979;32:563–576.
  11. Baumgartner RN, Chumlea WC, Roche AF: Bioelectric impedance phase angle and body composition. Am J Clin Nutr 1988;48:16–23.
  12. Ferranini E: The theoretical bases of indirect calorimetry: a review. Metabolism 1988;37:287–301.
  13. Simonson DC, DeFronzo RA: Indirect calorimetry: methodological and interpretative problems. Am J Physiol 1990;258:E399–E412.
  14. Harris JA, Benedict FG: A Biometric Study of Basal Metabolism in Man. Washington, Carnegie Institute of Washington, 1919, publ No 279.
  15. Aid to the Investigation of Peripheral Nerve Injuries; in Medical Research Council. War Memorandum, ed 2 rev. London, HMSO, 1943, pp 11–46.
  16. ALS CNTF Treatment Study (ACTS) Phase I-II Study Group: The amyotrophic lateral sclerosis functional rating scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996;53:141–147.
  17. Bensimon G, Lacomblez L, Meininger V, and ALS/Riluzole Study Group: A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585–591.
  18. Kanda F, Fujii Y, Takahashi K, Fujita T: Dual-energy X-ray absorptiometry in neuromuscular diseases. Muscle Nerve 1994;17:431–435.
  19. Nau KL, Bromberg MB, Forshew DA, Katch VL: Individuals with amyotrophic lateral sclerosis are in caloric balance despite losses in mass. J Neurol Sci 1995;129(suppl):47–49.
  20. Tandan R, Krusinski PB, Hiser JR, Howard DB, Barsotti S, Thornton C, Griggs RC: The validity and sensitivity of dual energy X-ray absorptiometry in estimating lean body mass in amyotrophic lateral sclerosis; in Proc 9th International Symposium on ALS/MND, Munich, Nov 16–18, 1998. Munich, ALS Association, 1998, p 48.
  21. Shimizu T, Hayashi H, Tanabe H: Energy metabolism of ALS patients under mechanical ventilation and tube feeding. Clin Neurol 1991;31:255–259.
  22. Poehlman ET: Regulation of energy expenditure in aging humans. J Am Geriatr Soc 1993;41:552–559.
  23. Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, Loeffler JP: Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA 2004;101:11159–11164.
  24. Bergeron C: Oxidative stress – its role in the pathogenesis of amyotrophic lateral sclerosis. J Neurol Sci 1995;129:81–84.
  25. Heales SJR, Bolanos JP, Stewart VC, Brookes PS, Land JM, Clark JB: Nitric oxide, mitochondria and neurological disease. Biochim Biophys Acta 1999;1410:215–228.
  26. McGeer PL, McGeer EG: The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195–218.
  27. Estevez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, Tarpey MM, Barbeito L, Beckman JS: Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999;286:2498–2500.
  28. Torreilles F, Salman-Tabcheh S, Guerin M, Torreilles J: Neurodegenerative disorders: the role of peroxynitrite. Brain Res Brain Res Rev 1999;30:153–163.
  29. Ciriolo MR, De Martino A, Lafavia E, Rossi L, Carri MT, Rotilio G. Cu, Zn-superoxide dismutase-dependent apoptosis induced by nitric oxide in neuronal cells. J Biol Chem 2000;275:5065–5072.
  30. Murphy M: Slip and leak in mitochondrial oxidative phosphorylation. Biochim Biophys Acta 1989;977:123–141.
  31. Beal MF: Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1998;1366:211–223.
  32. Markus HS, Cox M, Tomkins AM: Raised resting energy expenditure in Parkinson’s disease and its relationship to muscle rigidity. Clin Sci 1992;83:199–204.
  33. Toth MJ, Fishman PS, Poehlman ET: Free-living daily energy expenditure in patients with Parkinson’s disease. Neurology 1997;48:88–91.
  34. Poehlman ET, Dvorak RV: Energy expenditure, energy intake, and weight loss in Alzheimer disease. Am J Clin Nutr 2000;71(suppl):S650– S655.
  35. De Carvalho M, Nogueira A, Pinto A, Miguens J, Sales Luis ML: Reflex sympathetic dystrophy associated with amyotrophic lateral sclerosis. J Neurol Sci 1999;169:80–83.
  36. Dettmers C, Fatepour D, Faust H, Jerusalem F: Sympathetic skin response abnormalities in amyotrophic lateral sclerosis. Muscle Nerve 1993;16:930–934.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50